BIOMAT Database Logo BIOMAT Database Logo

[Treatment of hepatic encephalopathy with glucagon-insulin (author's transl)]. 1980

A Fujishima, and H Fujita, and M Saito, and Y Shirai, and M Suga, and Y Hosokawa, and Y Yokoyama, and H Kinoshita, and T Anzai

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D006501 Hepatic Encephalopathy A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5) Encephalopathy, Hepatic,Portosystemic Encephalopathy,Encephalopathy, Hepatocerebral,Encephalopathy, Portal-Systemic,Encephalopathy, Portosystemic,Fulminant Hepatic Failure with Cerebral Edema,Hepatic Coma,Hepatic Stupor,Hepatocerebral Encephalopathy,Portal-Systemic Encephalopathy,Coma, Hepatic,Comas, Hepatic,Encephalopathies, Hepatic,Encephalopathies, Hepatocerebral,Encephalopathies, Portal-Systemic,Encephalopathies, Portosystemic,Encephalopathy, Portal Systemic,Hepatic Comas,Hepatic Encephalopathies,Hepatic Stupors,Hepatocerebral Encephalopathies,Portal Systemic Encephalopathy,Portal-Systemic Encephalopathies,Portosystemic Encephalopathies,Stupor, Hepatic,Stupors, Hepatic
D006505 Hepatitis INFLAMMATION of the LIVER. Hepatitides

Related Publications

A Fujishima, and H Fujita, and M Saito, and Y Shirai, and M Suga, and Y Hosokawa, and Y Yokoyama, and H Kinoshita, and T Anzai
[Heterogeneity of plasma immunoreactive glucagon in patients with hepatic encephalopathy (author's transl)].
September 1980, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
A Fujishima, and H Fujita, and M Saito, and Y Shirai, and M Suga, and Y Hosokawa, and Y Yokoyama, and H Kinoshita, and T Anzai
Insulin, glucagon, aminoacid imbalance, and hepatic encephalopathy.
October 1976, Lancet (London, England),
A Fujishima, and H Fujita, and M Saito, and Y Shirai, and M Suga, and Y Hosokawa, and Y Yokoyama, and H Kinoshita, and T Anzai
[Pathogenesis of hepatic encephalopathy (author's transl)].
August 1977, Leber, Magen, Darm,
A Fujishima, and H Fujita, and M Saito, and Y Shirai, and M Suga, and Y Hosokawa, and Y Yokoyama, and H Kinoshita, and T Anzai
[Present-day therapy of hepatic encephalopathy (author's transl)].
December 1976, MMW, Munchener medizinische Wochenschrift,
A Fujishima, and H Fujita, and M Saito, and Y Shirai, and M Suga, and Y Hosokawa, and Y Yokoyama, and H Kinoshita, and T Anzai
[Continuous haemofiltration in encephalopathy associated with hepatic failure (author's transl)].
May 1982, La Nouvelle presse medicale,
A Fujishima, and H Fujita, and M Saito, and Y Shirai, and M Suga, and Y Hosokawa, and Y Yokoyama, and H Kinoshita, and T Anzai
[Insulin responses and its hepatic extraction with intravenous glucose and glucagon stimulation in obstructive jaundice (author's transl)].
June 1981, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
A Fujishima, and H Fujita, and M Saito, and Y Shirai, and M Suga, and Y Hosokawa, and Y Yokoyama, and H Kinoshita, and T Anzai
[Glucagon (author's transl)].
September 1976, Therapeutische Umschau. Revue therapeutique,
A Fujishima, and H Fujita, and M Saito, and Y Shirai, and M Suga, and Y Hosokawa, and Y Yokoyama, and H Kinoshita, and T Anzai
[Effect of glucagon on hepatic bile in obstructive jaundice (author's transl)].
April 1982, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
A Fujishima, and H Fujita, and M Saito, and Y Shirai, and M Suga, and Y Hosokawa, and Y Yokoyama, and H Kinoshita, and T Anzai
[Hyperammonemia and hepatic encephalopathy in cirrhotics receiving spironolactone (author's transl)].
November 1977, La Nouvelle presse medicale,
A Fujishima, and H Fujita, and M Saito, and Y Shirai, and M Suga, and Y Hosokawa, and Y Yokoyama, and H Kinoshita, and T Anzai
[Esophageal food impaction. Treatment by glucagon (author's transl)].
January 1981, Acta gastro-enterologica Belgica,
Copied contents to your clipboard!